NHS Progress and Business Update

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces an update on the Company's continued dialogue with NHS stakeholders with a view to fulfilling productivity requirements across the NHS.

Previous indications were that a central NHS decision would be made in relation to a potential contract for adoption of a widescale programme for Bleepa around the end of the 2025/26 NHS financial year (31 March 2026). The Company now understands that decisions will be delayed by at least 6-9 months due to NHS internal factors. Nevertheless, discussions have continued to progress positively with central NHS stakeholders regarding at scale opportunities for Bleepa which the Board believes have the potential to be aligned to new frontline digitisation funding which is expected to become available in the 2026/27 NHS financial year.

Despite the delayed decision, NHSE has extended Bleepa's existing licences at Queen Victoria Hospital NHS Foundation Trust ("QVH") (annualised contract value £495k) to cover the 9-month period ending in December 2026. This ensures that the Bleepa pathway programme can continue to expand within Sussex whilst discussions continue around the potential for a larger scale rollout. Bleepa's usage at QVH continues to grow in both user numbers and use cases. The Company recently partnered with Patients Know Best to deliver a pioneering new insomnia pathway in Sussex, and we are in active discussions with QVH around additional use cases, product optimisation and additional funding in this calendar year.

Focus on Core Growth Opportunities

Following discussion with the Royal Berkshire NHS Foundation Trust, the Company will not be renewing its contract for photocapture with the Trust which came to the end of its 3-year term at the end of March 2026. This is part of a managed process to focus on utilising internal resources to optimise Bleepa for core pathway opportunities which the Company believes have the potential to deliver significantly larger revenues.

The Bleepa pathway use case is also being demonstrated for internal pathways at the Northern Care Alliance NHS Foundation Trust where the Company has agreed a further annual contract extension with the Trust, providing the opportunity to further build the business case for expansion and funding opportunities.

The Board remains confident that the Company continues to provide a unique value proposition that could deliver significant impact against the NHS' primary objective of waitlist reduction and elective recovery. The Company remains in active dialogue with national NHS stakeholders underpinning confidence in the mid-term opportunity for Bleepa. The Company's cash position is being carefully managed and, based on current plans, provides a runway extending to mid-2027.

Dr Tom Oakley, CEO of Feedback, said:

"Despite the delay in the NHS's decision, we remain optimistic of a positive outcome. The additional funding to extend Bleepa licences at QVH demonstrates an ongoing commitment to our solutions.

"Whilst we await the outcomes of central NHS decisions, we will focus on expanding the programme at QVH and other pathway opportunities, whilst selectively exploring alternative opportunities to create shareholder value."